A5091450277- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Occupational and environmental lung diseases
- HER2/EGFR in Cancer Research
- Cancer Genomics and Diagnostics
- Pleural and Pulmonary Diseases
- Cancer Immunotherapy and Biomarkers
- Cancer therapeutics and mechanisms
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Gastric Cancer Management and Outcomes
- Neutropenia and Cancer Infections
- Hepatocellular Carcinoma Treatment and Prognosis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Diagnosis and Treatment
- PARP inhibition in cancer therapy
- Neuroendocrine Tumor Research Advances
- Peptidase Inhibition and Analysis
- Brain Metastases and Treatment
- Chronic Lymphocytic Leukemia Research
- Endometrial and Cervical Cancer Treatments
- Ovarian cancer diagnosis and treatment
- Multiple and Secondary Primary Cancers
- Cancer Treatment and Pharmacology
Maidstone Hospital
2016-2025
Maidstone and Tunbridge Wells NHS Trust
2013-2024
National Cheng Kung University Hospital
2013-2023
National Taiwan University Hospital
2013-2023
Kanagawa Cardiovascular and Respiratory Center
2013-2023
Taipei Veterans General Hospital
2013-2023
Universidad de Navarra
2021
Lilavati Hospital & Research Centre
2016
Royal Marsden Hospital
2004-2009
Royal Marsden NHS Foundation Trust
2004-2009
The LUX-Lung 3 study investigated the efficacy of chemotherapy compared with afatinib, a selective, orally bioavailable ErbB family blocker that irreversibly blocks signaling from epidermal growth factor receptor (EGFR/ErbB1), human 2 (HER2/ErbB2), and ErbB4 has wide-spectrum preclinical activity against EGFR mutations. A phase II afatinib in mutation-positive lung adenocarcinoma demonstrated high response rates progression-free survival (PFS).
Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both EGFR-TKI–sensitizing and EGFR T790M resistance mutations. A phase 3 trial compared first-line osimertinib with other EGFR-TKIs in patients mutation–positive advanced non–small-cell lung cancer (NSCLC). The showed longer progression-free survival than comparator (hazard ratio for disease progression or death, 0.46). Data from final...
Afatinib 40 mg/day is approved for first-line treatment of EGFR mutation-positive non-small-cell lung cancer (NSCLC). In the case drug-related grade ≥3 or selected prolonged 2 adverse events (AEs), dose can be reduced by 10 mg decrements to a minimum 20 mg. Here, we evaluate influence afatinib reduction on AEs, pharmacokinetics and progression-free survival (PFS) in phase III LUX-Lung 3 6 (LL3/6) trials.Treatment-naïve patients with advanced NSCLC LL3 (global) LL6 (China, Thailand, South...
Osimertinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), potently and selectively inhibits EGFR-TKI-sensitizing EGFR T790M resistance mutations. In the Phase III FLAURA study (NCT02296125), first-line osimertinib improved outcomes vs comparator EGFR-TKIs in EGFRm advanced non-small cell lung cancer. This analysis identifies acquired mechanisms to osimertinib. Next-generation sequencing assesses circulating-tumor DNA from paired plasma samples (baseline disease...
Extended pleurectomy decortication for complete macroscopic resection pleural mesothelioma has never been evaluated in a randomised trial. The aim of this study was to compare outcomes after extended plus chemotherapy versus alone.
LBA7500 The full, final text of this abstract will be available at abstract.asco.org 12:01 AM (EDT) on Monday, June 4, 2012, and in the Annual Meeting Proceedings online supplement to 20, issue Journal Clinical Oncology. Onsite Meeting, printed Monday edition ASCO Daily News.
Introduction Mesothelioma remains a lethal cancer. To date, systemic therapy with pemetrexed and platinum drug the only licensed standard of care. As median survival for patients mesothelioma is 12.1 months, surgery an important consideration to improve and/or quality life. Currently, two surgical trials have been performed which found that neither extensive (extra-pleural pneumonectomy) or limited (partial pleurectomy) improved (although there was some evidence life). Therefore, clinicians...
The LUX-Lung 3 study investigated the efficacy of chemotherapy compared with afatinib, a selective, orally bioavailable ErbB family blocker that irreversibly blocks signaling from epidermal growth factor receptor (EGFR/ErbB1), human 2 (HER2/ErbB2), and ErbB4 has wide-spectrum preclinical activity against
LBA8002 Background: The currently approved frontline TXs for PM are the combination of ipilimumab/nivolumab or platinum plus pemetrexed. addition B to C has been shown improve overall survival in a randomized clinical trial. While combined immunotherapy single agent with is superior alone, there potential synergistic triple C, B, and immunotherapy. Methods: BEAT-meso (NCT03762018) an international open-label, 1:1 phase III trial, stratified by histology stage. objective determine efficacy...
LBA7500 Background: Afatinib (A) is a selective, orally bioavailable, irreversible ErbB family blocker of EGFR (ErbB1), HER2 (ErbB2), and ErbB4. This global study investigated the efficacy safety A compared with pemetrexed/cisplatin (PC) in pts mutation positive advanced lung adenocarcinoma. Methods: Following central testing for mutations (companion diagnostic TheraScreen RGQ PCR kit), 345 (stage IIIB/IV, PS 0–1, chemo-naive) were randomized 2:1 (A: 230; PC: 115) to daily 40 mg or iv PC...
Small cell lung cancer (SCLC) responds well to chemoradiotherapy but frequently relapses. Here, we evaluate activity and safety of the poly (adenosine diphosphate (ADP)-ribose) polymerase (PARP) inhibitor olaparib as maintenance treatment for patients with chemoresponsive SCLC.
In retrospective analyses of patients with nonsquamous non-small-cell lung cancer treated pemetrexed, low thymidylate synthase (TS) expression is associated better clinical outcomes. This phase II study explored this association prospectively at the protein and mRNA-expression level.Treatment-naive (stage IIIB/IV) had four cycles first-line chemotherapy pemetrexed/cisplatin. Nonprogressing continued on pemetrexed maintenance until progression or maximum tolerability. TS...
Background: In the Phase III FLAURA study (NCT02296125), osimertinib showed superior efficacy compared with standard of care (SoC) EGFR-TKIs in patients (pts) previously untreated EGFRm advanced NSCLC. Here, we report preliminary data on mechanisms acquired resistance to pts who progressed during study. Methods: Pts (tissue, ex19del/L858R) NSCLC (N = 556) were randomised 1:1 80 mg once daily (QD; n 279) or SoC EGFR-TKI (n 277, gefitinib 250 QD erlotinib 150 QD). Paired plasma samples...
Abstract Background: Malignant Pleural Mesothelioma (MPM) is a rare cancer with limited treatment options. Large-scale deep biological description of intratumor heterogeneity at single-cell resolution still missing. Recent studies fresh tumor biopsies analyzed only few patients, limiting population heterogeneity. Objective: To describe in FFPE tissues the cell and microenvironment untreated MPM patients. Method: Of 400 enrolled patients BEAT-MESO clinical trial (NCT03762018), 220 had...